Biosimilar Herceptin is launched in the UK

The UK’s National Health Service (NHS) now has access to a lowercost alternative to Roche’s Herceptin (trastuzumab) treatment for forms of breast and gastric cancer, after Merck Sharp & Dohme announced the launch of partner Samsung Bioepis’ Ontruzant (trastuzumab) biosimilar in the UK.